Search

Your search for "odyy" returned the following results.
Filter Results:
News Articles

Odyssey Health, Inc. (ODYY) To Give Corporate Update at Scheduled Annual Meeting of Stockholders in January 2023

December 1, 2022

Odyssey Health (OTC: ODYY), a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs, just announced plans to hold its Annual Meeting of Stockholders, scheduled for January 12, 2023. The meeting will be an excellent platform for the company and its management to update its stockholders on the […]

News Articles

Odyssey Health, Inc. (ODYY) Development of Neuropharmaceuticals for TBIs and CNS Maladies, Portends Competitiveness in Area of Unmet Medical Needs

November 29, 2022

Concussion head injuries are becoming more widely talked about among sports enthusiasts since two such head injuries in a week’s time required the Miami Dolphins’ quarterback to be carried off the field during a September game and to experience significant memory loss afterward (https://ibn.fm/AiVI6). Football season naturally lends itself to concerns about concussions, known as […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Reports on Concussion Drug Progress, Provides Corporate Update

November 23, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has released an update on its concussion drug-development program. According to the release, in March 2022 the company acquired key intellectual property (“IP”) to a concussion drug, along with all rights to that drug. During […]

News Articles

Odyssey Health, Inc. (ODYY) Expands Executive Team of New Subsidiary in Strategic Move to Strengthen Marketing of Concussion, Neurological Therapies

November 21, 2022

Brain injuries affect all aspects of society, from recreational youth athletics to military trauma interventions Despite the commonality of brain concussion injuries — more than 5 million a year in the United States alone — no FDA-approved therapy exists Medical technology innovator Odyssey Health Inc. is working toward a commercialized product treatment solution to the […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Upcoming Annual Meeting of Stockholders

November 15, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, has scheduled its Annual Meeting of Stockholders; the meeting is slated for Jan. 12, 2023. According to the announcement, any proposals to be considered for the meeting should be sent to the company’s principal executive […]

News Articles

Odyssey Health, Inc. (ODYY) Focuses on Medical Devices Market with US Patent Application on Breath-Propelled Intranasal Delivery Device

November 14, 2022

Odyssey filed for US and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device that effectively deposits concentrated drug deep into the nasal cavity for the treatment of CNS injury disease or disorder The application follows the successful completion of the second Cohort of Odyssey’s Phase I MAD clinical trial, which saw the […]

News Articles

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Poised to Potentially Reduce Long-Term Risks Associated with Concussion

November 9, 2022

Odyssey Health is a medical company specializing in the development of unique, life-saving medical products that provide solutions to unmet clinical needs, one of which is concussion, which currently does not have an FDA-approved drug The company has developed the PRV-002 drug candidate, which is designed to be administered intranasally where pre-clinical results have shown […]

News Articles

New Pharmaceutical Subsidiary Geared to Aid Odyssey Health, Inc. (ODYY) Development of Novel Solutions for Brain Related Medical Treatments

November 7, 2022

Odyssey Health Inc. is a medical product developer with a mission of filling unmet needs when it comes to acute emergencies involving patients’ central nervous systems The company recently announced the formation of a wholly owned subsidiary to help Odyssey develop its products as they move through the regulatory process Odyssey’s solutions include a breath-powered […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Expansion of Executive Team

November 3, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a medical technology company focused on developing unique, life-saving medical products, is expanding its executive team. The expansion is part of ODYY’s support of and commitment to Odyssey NeuroPharma, the company’s newest entity. Additions to the executive team include Erik Emerson, named chief commercial officer, and […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Files for Patent Protection on Novel Breath-Propelled Intranasal Brain-Drug Delivery Device

November 1, 2022

Odyssey Health (OTC: ODYY) has filed for United States and global patent protection on its novel breath-propelled, intranasal brain-drug delivery device (“Nasal Device”). As previously announced, Odyssey’s recently completed phase I study to treat concussion successfully used Odyssey’s Nasal Device and drug combination. “We were very pleased with the functionality and performance of the Nasal […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Pleased with Safety Profile of Its PRV-002 Concussion Treatment

October 31, 2022

Odyssey Health (OTC: ODYY) recently announced the completion of the second Cohort of its Phase I Multi-Day Ascending Dosing (“MAD”) clinical trial. “Odyssey’s trial involved administering its novel drug to treat concussions, PRV-002, to healthy human subjects to determine drug safety. A total of 40 healthy subjects took part in the study. In Cohort I, […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Expedite Return to Work, Play Following Concussive Episode

October 26, 2022

Odyssey Health (OTC: ODYY), a medical company with a focus in the area of life-saving medical solutions, has developed a fully synthetic, non-naturally occurring neurosteroid known as PRV-002 intended to treat concussion or mild traumatic brain injury (“mTBI”). “Designed to be administered within a few minutes of a concussive episode, PRV-002 induces an intracellular steroid […]

News Articles

Odyssey Health, Inc. (ODYY) Updates Progress of its Concussion Drug Development Program; Communicating with the FDA for permission to start phase II clinical trial of its PRV-002 Drug Candidate

October 18, 2022

Odyssey acquired IP and all rights to PRV-002, its lead drug candidate for the treatment of concussions, on March 1, 2021, and has since made notable progress in a strategic move to have the drug approved by the FDA Since the acquisition, the company has completed IND enabling studies and all cohorts for Phase I […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Designed to Mitigate Short- and Long-Term Effects of mTBI

October 17, 2022

Odyssey Health (OTC: ODYY) early last year acquired PRV-002, a drug candidate for concussed patients to mitigate both short-term and long-term consequences of concussion. Concussion or mTBI “is caused by a jolt, blow or force to the head that changes the brain’s function. This change often results in myriad consequences ranging from emotional and somatic […]

News Articles

Odyssey Health, Inc. (ODYY) Seeking to Provide Solution to Concussion-Prone Military and NFL with Development of PRV-002 Drug Candidate

October 14, 2022

Odyssey Health is a medical company developing unique, life-saving products that address unmet clinical needs such as concussion, which does not have an FDA-approved therapeutic The company has developed PRV-002, a neurosteroid for the treatment of concussion, and an intranasal delivery device that delivers the drug into the upper chamber of the nasal cavity for […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Formation of Subsidiary Focused on Treating Neurological Disorders

October 11, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the formation of Odyssey Neuropharma Inc. According to the update, the wholly owned subsidiary will focus on developing drugs to treat neurological disorders. The blood-brain barrier (“BBB”) represents a significant obstacle for drug delivery to the brain, and many drugs […]

News Articles

Odyssey Health, Inc. (ODYY) PRV-002 Compound Takes on Heightened Significance Following Recent Concussion of Dolphins Quarterback Tua Tagovailoa, and the NFL and NFLPA’s Announcement on Changes to Concussion Protocol

October 10, 2022

The concussion controversy surrounding Tua Tagovailoa has prompted both the NFL and the NFLPA to revisit the league’s concussion protocol in a move designed to enhance player safety In the wake of this controversy, Odyssey is emphasizing the potential value of its PRV-002 novel compound for the treatment of concussions and the benefit of the […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Issues Recap of Concussion Drug Development Program

October 6, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today provided a recap of its concussion drug development program. Concussions affect millions worldwide and represent an ‘unmet’ medical need, while repetitive concussions can increase the risk of developing chronic traumatic encephalopathy (“CTE”) and other neuropsychiatric disorders. Since acquisition of the intellectual […]

News Articles

Odyssey Health, Inc. (ODYY) Completes Successful Phase I Clinical Trial Showing PRV-002 Concussion Drug Candidate was Safe and Well Tolerated

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs With concussion representing a high unmet need as there is currently no FDA-approved drug, Odyssey is developing a drug formulation, PRV-002, to be administered to concussed patients; the drug candidate is currently undergoing clinical evaluation […]

News Articles

Odyssey Health, Inc. (ODYY) Building on Safety Profile of Concussion Pharmaceutical Treatment, PRV-002, in its Phase I MAD Clinical Trial

October 4, 2022

Odyssey successfully completed the second Cohort of its Phase I MAD clinical trial, proving the safety profile of its concussion pharmaceutical treatment, PRV-002 This study built on the success of Cohort I, where the drug was well tolerated and proved safe, with no severe adverse events reported The company’s Phase I Single Ascending Dose (“SAD”) […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Dissolves Sports Board, Releases Statement on Drug-Development Program

October 3, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing a unique drug to treat concussion, has announced that, in order to keep its focus, it has dissolved its sports advisory board. According to the announcement, the sports board has been a distraction for the company, and in order to continue […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Successful Completion of Phase I Clinical Trial for PRV-002

September 28, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the completion of all cohorts for its Phase I Single Ascending Dosing (“SAD”) and Multiple Ascending Dosing (“MAD”) clinical trial. Odyssey’s trial involved administering its novel drug to treat concussion, PRV-002, to healthy human subjects. The drug was safe and […]

News Articles

Odyssey Health, Inc.’s (ODYY) Brain-Related Drug Development Programs Taking Aim at Conditions with High Unmet Clinical Needs

Odyssey is a medical company focused on products that offer clinical advantages to unmet clinical needs Its brain-related drug development programs are currently focused on treatments for concussion and the Niemann Pick Type-C (“NPC”) disease, both of which do not currently have approved treatments The company is also developing medical devices such as the intranasal […]

News Articles

Odyssey Health, Inc. (ODYY) Reports Added Evidence of Proposed Concussion Therapy’s Safety at High Doses

September 26, 2022

Medical product developer Odyssey Health Inc. is dedicated to creating solutions for a variety of life-quality situations, such as early detection of heart disease, saving choking victims and treating nervous system ailments Odyssey Health’s primary focus has been advancing its combined device and drug solution for brain concussion injuries through the clinical test process to […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Eyes Intranasal Brain Targeting as Key to Success of PRV-002

September 22, 2022

Odyssey Health (OTC: ODYY) announced in August the completion and findings of cohort I of the multiday ascending dosing (“MAD”) stage of its ongoing phase I clinical trial showing that PRV-002 was safe and well tolerated. A recent article reads: “Additionally, pharmacokinetic (‘PK’) analysis of the data from the first cohort provided new information that […]

News Articles

Odyssey Health, Inc.’s (ODYY) PRV-002 Drug Candidate Designed to Immediately Mitigate the Effects of Concussion on Brain Function

September 15, 2022

Odyssey Health is a medical company focused on unique, life-saving medical products that offer clinical advantages to unmet clinical needs The company is currently developing a treatment for concussion, a condition that currently does not have an FDA-approved treatment despite having both short- and long-term consequences Through animal studies, Odyssey has so far evidenced that […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Reports Successful Safety Outcomes for Most Recent Phase of Concussion Drug Trial

September 13, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products, has completed the safety measures for the second cohort of its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to evaluate the company’s novel drug to treat concussion: PRV-002. […]

News Articles

Odyssey Health, Inc. (ODYY) Planning Phase 2 Trials of PRV-002 for Unmet Medical Needs in Concussion Therapies

September 12, 2022

Medical costs for concussions total $20 billion in the United States, a need for which there is no FDA-approved treatment The CDC estimates that more than 50% of people suffering a traumatic brain injury become moderately or severely disabled and have shorter life spans Odyssey provides a portfolio of diverse technologies and related medical products […]

News Articles

Odyssey Health, Inc. (ODYY) Receives Approval to Proceed with Cohort II of Its Phase I Trial’s Multiday Ascending Dosing Stage

September 7, 2022

Medical company Odyssey Health has received approval from the Safety Review Committee to start Cohort II of its Phase I trial’s Multiday Ascending Dosing (“MAD”) stage The approval follows evidence that Odyssey’s PRV-002 concussion drug candidate was safe and well-tolerated, as seen in Cohort I of the MAD stage The pharmacokinetic analysis also supports the […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Featured in NeurologyLive(R) Article

August 29, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent NeurologyLive(R) article. The piece, titled “Concussion Treatment PRV-002 Demonstrates Safe, Tolerable Profile in Phase 1 Trial” and written by Marco Meglio, discusses positive results from a multiday ascending dose trial. “In cohort 1 of the multiday ascending […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc.’s (ODYY) PRV-002 Poised to Offer First-of-Its-Kind Responsiveness to Concussion

August 26, 2022

Odyssey Health (OTC: ODYY), a medical device innovator and biopharmaceutical product developer, has been advancing a proposed solution for brain injury from concussive forces. “Odyssey Health’s novel compound PRV-002 is the combination of a device and the medicine it delivers to treat concussions during the first moments after their occurrence, before permanent or long-term damage […]

News Articles

Phase I Trial Advance for Concussion Drug Leads Odyssey Health, Inc. (ODYY) to Prepare to Launch the Efficacy Analysis Stage for its Product

August 25, 2022

Brain concussion injuries have commanded a new level of respect in recent years as military personnel, athletes and care center administrations seek remedies rather than simply encouraging people to “shake off” a hard hit to the head Odyssey Health is advancing clinical trials for its novel PRV-002 drug / device solution for treating concussion patients […]

News Articles

Odyssey Health, Inc. (ODYY) Continues to Report Positive Results from Ongoing Phase I Clinical Trial Evaluating Safety, Efficacy of PRV-002 Concussion Drug Candidate

August 22, 2022

Odyssey Health is a medical company focused on developing unique, life-saving medical products that offer clinical advantages for unmet clinical needs Recently, the company reported positive results from Cohort I of its Multi-Day Ascending Dosing (“MAD”) portion of its Phase I clinical trial, coming weeks after the successful completion of Phase I Single Ascending Dosing […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Achieves Positive Safety Outcomes for Concussion Drug in Multiple Ascending Dosing Trial

August 18, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, has completed safety measures for its phase I multiday ascending dosing (“MAD”) clinical trial. According to the announcement, the trial is designed to study PRV-002, the company’s proprietary […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Featured on ‘Dr. Finance Live’ Podcast

August 16, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured on “Dr. Finance Live,” a podcast series focused on changing the way we think about economics and finance. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for Odyssey Health, joined the recent broadcast, hosted […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Shares Favre Interview

August 11, 2022

Odyssey Health (OTC: ODYY), formerly Odyssey Group International and a company focused on developing unique, life-saving medical products including a novel compound for the treatment of concussion, is sharing an interview by NFL Hall of Famer Brett Favre. During the interview, hosted by Bubba, the Love Sponge(R), Favre talks about the many concussions he received […]

News Articles

Odyssey Health, Inc. (ODYY) Redesigns Website, Corporate Presentation, to Update Information on Medical Products, Including Concussion Therapy

Odyssey Health Inc. is a medical product developer advancing treatments for conditions ranging from choking to neurodegenerative maladies The company’s flagship candidate is a drug-device combination for treating mild brain injuries (“MTBIs”) known as PRV-002, which is currently being used in clinical testing with human volunteers Odyssey Health recently announced a redesign of its website […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Announces Positive Results from MAD Arm of Phase I Trial

August 10, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the completion and safety findings from Cohort I of its Multi-Day Ascending Dosing (“MAD”) arm for its phase I clinical trial. The trial is administering PRV-002, Odyssey’s novel drug to treat concussion, to healthy human subjects. According to the update, […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc.’s (ODYY) Dr. Jacob VanLandingham, Brett Favre Featured in ‘Get Authentic’ Podcast

August 9, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, was featured in a recent episode of Get Authentic with Marques Ogden, a podcast series delivering honest, unfiltered and real-time stories from legendary athletes and industry leaders. NFL Hall of Famer Brett Favre and Dr. Jacob VanLandingham, head of drug development for […]

InvestorNewsBreaks

InvestorNewsBreaks – Odyssey Health Inc. (ODYY) Unveils New Corporate Website

August 4, 2022

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the launch of its new corporate website. Consistent with the company’s recent name change, the new website was designed to better reflect Odyssey Health’s mission and focus while also improving communication strategies with current and potential shareholders, institutions, and various […]

No ResultsNo content matches your search/filter.

 

 

 

Get Started with InvestorWire

To distribute a release in the next 24 hours. Contact our client services team.

(310) 299-1717

Distribute a press release. Submit your release to get started.

Submit Press Release

Set up a Live demonstration. Schedule a date and time that works for you.

Schedule a LIVE Demo

Press Distribution

Explore Press Distribution Solutions

All releases include an unlimited word count* with full wire-grade syndication, our press release enhancement service, and a follow-up InvestorNewsBreak article distributed to thousands of editorial syndication partners.

Discover Add-on Solutions

Increase the impact of your achievements by adding these exclusive solutions from InvestorWire, delivered in conjunction with the InvestorBrandNetwork (IBN).